89
Participants
Start Date
October 31, 2015
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
ETC-1922159
Oral administration
Pembrolizumab
IV administration
Duke University Medical Center, Duke Cancer Center, 20 Duke Medicine Circle, Site 206, Durham
Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place, Site 205, St Louis
University of Kansas Medical Center, 4350 Shawnee Mission Parkway, Suite 2310, MS 6004, Site 210, Fairway
Department of Investigational Cancer Therapeutics, 1400 Holcombe Blvd., Unit 455, Site 201, Houston
University of Colorado Hospital Anschutz Cancer Pavilion, 12648 East 17th Avenue; MSF 700, Site 202, Aurora
University of Arizona Cancer Center, 3838 N. Campbell Avenue, RM 2111, Site 203, Tucson
Chao Family Comprehensive Cancer Center,Stern Center for Cancer Clinical Trials and Research, 101 City Drive South, Site 209, Orange
Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mail Code Cr 9-4, Site 211, Portland
National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Site 101, Singapore
National Cancer Centre Singapore, 11 Hospital Drive, Site 102, Singapore
Oregon Health and Science University-Knight Cancer Institute, 3485 S Bond Ave., Mail code 0C14CTSite 211, Portland
Collaborators (1)
PPD Development, LP
INDUSTRY
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
OTHER_GOV